Liu David Y 4
4 · Protagonist Therapeutics, Inc · Filed Aug 19, 2021
Insider Transaction Report
Form 4
Liu David Y
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-08-17$0.87/sh+10,000$8,700→ 73,033 total - Exercise/Conversion
Stock Option (right to buy)
2021-08-17−10,000→ 13,767 totalExercise: $0.87Exp: 2023-09-26→ Common Stock (10,000 underlying) - Sale
Common Stock
2021-08-17$47.56/sh−14,779$702,889→ 58,254 total
Footnotes (4)
- [F1]Includes an aggregate of 606 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 7, 2021.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.10 to $48.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The stock option is vested in full.